INS and type 2 diabetes mellitus: The number of patients experiencing hypoglycemic events was similar for Icodec and once-daily basal insulin doses in T2D [50] but not T1D (ONWARDS 6), where Icodec was associated with a statistically significant higher risk of clinically relevant or severe hypoglycemic events.